The European Union will buy an extra 100 million doses of Pfizer and BioNTech’s COVID-19 vaccine, bringing the total from the two firms to 300 million doses, European Commission President Ursula von der Leyen said on Tuesday.
“We decided to take an additional 100 million doses of the BioNTech/Pfizer vaccine, which is already being used to vaccinate people across the EU,” she said on Twitter.
“We will therefore have 300 million doses of this vaccine, which was assessed as safe and effective,” von der Leyen added.
The plan comes after some of the vaccine candidates ordered by the EU faced unexpected delays in clinical trials, forcing the bloc and other wealthy nations to rely on shots from fewer manufacturers than initially planned.
The Pfizer/BioNTech shot, the first COVID-19 vaccine to be approved by Western drugs regulators, is being rolled out in countries including Britain and the US.
Under the EU contract, the two firms have committed to rapidly deliver 200 million doses after regulatory approval for 15.5 euros ($18.8) apiece, EU officials told Reuters in November.
The extra 100 million doses would be supplied at the same price, but with the timetable to be negotiated, EU officials said.
All 300 million doses are expected to be delivered in 2020 and 2021, Pfizer/BioNTech said in a statement on Tuesday.
“The additional 100 million doses will be delivered in 2021, supporting the vaccination campaigns, which started two days ago in all 27 member states,” BioNTech Chief Executive Officer Ugur Sahin said.
With a population of 450 million, the bloc is now relying on the 200 million Pfizer shots it has already ordered for its first vaccinations.
In January, the EU is also expected to approve the shot developed by Moderna. It has an initial order of 80 million doses, with an option for 80 million more that will be exercised.
Both the Pfizer and Moderna vaccines require two doses per person. In total, the EU has booked nearly 1.3 billion vaccines in deals with Pfizer/BioNTech, Moderna, Johnson & Johnson, AstraZeneca/Oxford, Sanofi/GSK and CureVac, and has options to buy another 660 million.
Coronavirus: New York probes possibly fraudulently obtained COVID-19 vaccinesA health care provider in New York may have fraudulently obtained COVID-19 vaccines and diverted them to members of the public in violation of ... Coronavirus
Coronavirus: US COVID-19 test requirement for UK travelers should extend to otherA senior US public health official on Tuesday said the coronavirus testing the United States now is requiring for travelers from Britain should ... Coronavirus
Coronavirus: CDC forecasts 400,000 COVID-19 deaths in US before Trump's exitThe Centers for Disease Control and Prevention now predicts the U.S. will see 400,000 coronavirus deaths by Jan. 20, when President Donald Trump is to ... Coronavirus